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Introduction
Regulatory CD4+ T cells expressing FOXP3 (Tregs) play a critical 
role in tolerance by modulating immune responses to both endoge-
nous and exogenous antigens (1, 2). FOXP3 is required for Treg 
development and function, and FOXP3 deficiency leads to systemic 
autoimmunity (reviewed in refs. 1, 2). Tregs comprise approxi-
mately 10% of peripheral CD4+ cells and primarily arise as a dis-
tinct lineage in the thymus (natural Treg [nTreg]). However, periph-
eral FOXP3– conventional CD4+ T cells (Tconvs) can convert into 
“induced” FOXP3+ Tregs (iTregs) in certain microenvironments, 
such as the gut, where they help maintain mucosal tolerance (3–5).
Given their dominant role in induction and maintenance of 
tolerance, there has been great interest in therapeutic manipula-
tion of Tregs. The adoptive transfer of exogenous Tregs requires 
massive ex vivo expansion, and, despite recent progress, concerns 
over Treg purity and stability remain (6). Alternatively, toler-
ance may be enhanced by expanding Tregs in vivo. iTregs can be 
induced under specialized circumstances (2, 5, 7–11). While this 
can contribute to systemic tolerance, induction of iTregs during 
an active immune response has been observed primarily in TCR 
transgenic models. The extent to which this occurs in a polyclonal 
setting with typical antigen affinities remains unclear (12).
An approach that has received less attention is the specific 
expansion of preexisting Tregs. Endogenous or transferred Tregs 
in WT mice undergo significantly greater homeostatic prolifer-
ation (HP) than Tconvs, and Treg numbers are very sensitive to 
changes in proliferation or survival (13–16). Peripheral homeostasis 
is dependent on antigen presentation by DCs, since Treg number 
and HP are reduced when DCs lack MHC class II (17). Moreover, 
CD28 is required to maintain HP and peripheral Treg numbers 
(16, 18–20). This is only partially attributable to decreased IL-2 
production by Tconvs in the absence of CD28 (18). In this regard, 
IL-2 neutralization decreases Treg proliferation and cell number 
and can precipitate autoimmunity (14, 21), whereas exogenous 
IL-2 can expand Tregs (as well as NK cells and cytotoxic T lym-
phocytes (22–24). How peripheral homeostasis of Tregs can best 
be targeted to promote tolerance remains to be determined.
We showed previously that anti-CD45RB treatment induces 
donor-specific tolerance in stringent murine allograft models, and 
this is dependent on Tregs and induction of CTLA-4 on CD4+ cells 
(25–29). This raised the possibility that anti-CD45RB acts through 
generation of Tregs. We now show that anti-CD45RB nearly 
doubled both the frequency and number of endogenous Tregs 
in WT mice, due to specific enhancement of nTreg proliferation 
in response to antigen. Surprisingly, CD45 ligation preferentially 
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Treg numbers returned to baseline by day 14 (data not shown). 
This increase in Tregs occurred without affecting surface expres-
sion of activation markers on FOXP3+ or on FOXP3– cells (Fig-
ure 1D), whereas anti-CD45RB decreased CD45RB expression 
on CD4+ (Tconv) cells, as previously described (25). Moreover, 
CD4+CD25+ cells sorted from untreated and anti-CD45RB–
treated mice were equally potent on a per cell basis at suppress-
ing CD25– T cells in vitro (Figure 1E). These data suggest that 
the increased FOXP3+CD4+ cells, induced by anti-CD45RB, are 
fully functional Tregs.
Anti-CD45RB–mediated increase in Tregs occurs in the periphery. 
Anti-CD45RB could increase Tregs through biologically distinct 
mechanisms. To rule out an effect on thymic output, we showed 
that anti-CD45RB increased Treg numbers in euthymic and 
thymectomized mice equally (Figure 2A). Concordantly, thymec-
tomy did not prevent anti-CD45RB–induced prolongation of islet 
allograft survival by anti-CD45RB (29). This suggests that anti- 
CD45RB acts on Tregs in the periphery. To confirm this, congenic 
CD4+ cells were adoptively transferred into replete naive congenic 
WT mice with or without anti-CD45RB treatment. Consistent 
with the increase in endogenous FOXP3+ cells (Figure 1, A and 
B), anti-CD45RB increased both the percentage (data not shown) 
and absolute number of transferred CD4+ cells expressing FOXP3+ 
(2.6-fold), without affecting FOXP3– cells (Figure 2B).
CD45 ligation specifically expands nTregs by enhancing their HP. 
The increase in Tregs in the periphery induced by anti-CD45RB 
could have resulted from the de novo induction of iTregs and/or 
enhanced Treg/DC interactions in vivo, promoting NFAT activa-
tion, which was required for Treg expansion. Collectively, these 
findings demonstrate novel cellular and molecular mechanisms 
by which Tregs can be expanded in vivo for therapeutic purposes.
Results
Anti-CD45RB induces FOXP3+ Tregs in vivo. Since allograft sur-
vival mediated by anti-CD45RB is dependent on CD25+ cells and 
anti-CD45RB augments CTLA-4 expression (27–29), we asked 
whether anti-CD45RB induces Tregs in vivo. As previously shown, 
anti-CD45RB increased the percentage of CD4+ cells express-
ing CTLA-4 almost 2-fold (Figure 1A). We now show that anti- 
CD45RB also significantly augmented the frequency of splenic 
CD4 cells expressing FOXP3 from an average of 13.8% to 21.3% 
on day 10 (Figure 1A). This occurred without depletion of CD4+ 
Tconvs (Figure 1C and Figure 2B). Notably, anti-CD45RB increased 
FOXP3 expression in both alloantigen-exposed mice and naive 
mice, indicating that the expansion occurred independently of 
exogenous antigen (Figure 1A). The increased CD25 and CTLA-4 
expression on CD4+ cells in response to anti-CD45RB occurred 
entirely on FOXP3+ cells, which, for the most part (70%–80%), 
coexpressed these molecules (Figure 1A). Treatment with control 
IgG mAb had no effect on Tregs or FOXP3.
The increased percentage of FOXP3+CD4+ cells induced by 
anti-CD45RB was associated with a similar 1.6- to 1.9-fold increase 
in the absolute number of FOXP3+, CD25+, and CTLA-4+CD4+ 
cells in spleens (Figure 1B) and lymph nodes (data not shown). 
Figure 1. Anti-CD45RB treatment acutely induces FOXP3+ Tregs in the periphery. (A) Representative FOXP3, CTLA-4, and CD25 expression on day 10 by flow 
cytometry on splenic CD4+ T cells from mice that received control IgG, alloantigen (Allo) and control IgG, anti-CD45RB (day –1, 0, and 5), or alloantigen and 
anti-CD45RB. Numbers represent mean percentage ± SD expression in live CD4+ T cells. *P < 0.05 vs. control IgG, **P < 0.05 vs. alloantigen and control IgG  
(n = 8–19 mice per group from 4 independent experiments). (B) Number of splenic FOXP3+, CD25+, and CTLA-4+CD4+ cells in each group of mice on day 10 
relative to that in naive untreated control mice (n = 3–14 mice per group). *P < 0.05 vs. naive or untreated and alloantigen. (C) Number of FOXP3–CD4+ cells 
from spleens of mice treated with anti-CD45RB (day 10) relative to that in untreated mice (n = 8–10 mice per group, from 3 independent experiments; NS, not 
significant). (D) Representative flow cytometry histograms of CD69, CD44, CD62L, and CD45RB expression on FOXP3+ and FOXP3–CD4+ cells from naive and 
anti-CD45RB–treated mice (day 10). (E) Representative in vitro suppression by Tregs from anti-CD45RB–treated and untreated mice. Sorted CD4+CD25+ cells 
from naive (untreated) or anti-CD45RB–treated mice (day 10) were cultured in varying numbers with irradiated allogeneic splenocytes (BALB/c stimulators) 
and naive CD4+CD25– responder cells. Proliferation was assessed after 5 days. n = 4–6 mice per group from 2 independent experiments. No statistical differ-
ence between treated and naive mice was observed at any cell ratio.
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undergoing rapid HP, with a near doubling of the 
fraction that underwent >7 divisions after anti- 
CD45RB treatment (31% ± 7%), compared with that 
after control IgG (18% ± 6%; Figure 4A). Accord-
ingly, the proliferation and replication indexes of 
transferred nTregs were significantly increased 
upon anti-CD45RB treatment, compared with those 
upon treatment with control IgG (Supplemental Fig-
ure 1A; supplemental material available online with 
this article; doi:10.1172/JCI74087DS1). Overall, this 
led to a 2.3-fold increase in number of transferred 
FOXP3+ cells and a 3-fold increase in number of 
Tregs undergoing proliferation (Figure 4B). Anti- 
CD45RB also significantly increased the number of 
nonproliferating Tregs recovered (Figure 4B). How-
ever, on average, 74% of the increase in number of 
Tregs after CD45 ligation occurred in proliferating 
cells (Figure 4C). Taken together, our data demonstrate that 
anti-CD45RB specifically expands nTregs.
These results were corroborated by adoptive transfer of whole 
CD4+ T cells from congenic mice into replete WT animals. Ten days 
after transfer, anti-CD45RB significantly increased proliferation 
of Tregs from 39% (untreated) to 67% (after anti-CD45RB treat-
ment), resulting in a 4-fold increase in the number of proliferating 
Tregs (Figure 4, D and E). Transferred FOXP3– cells (Tconvs) in 
these animals remained unaffected. Concordantly, anti-CD45RB 
increased HP of endogenous Tregs, with an average of 32% incor-
porating BrdU over 3 days in treated animals compared with 20% 
in untreated animals, while HP of endogenous FOXP3– CD4+ was 
unaffected (Figure 4F). Thus, Treg HP can be specifically targeted 
by anti-CD45RB, leading to a significant increase in Treg number.
Based on the increase in nonproliferating cells (Figure 4B), 
anti-CD45RB may also enhance Treg survival. In this regard, 
we found that CD45 ligation significantly decreased apoptosis 
in Tregs harvested from spleens of mice on day 10 (Supplemen-
tal Figure 1B). Since TGF-β receptor signaling has been shown to 
the expansion of nTregs. To determine whether anti-CD45RB 
induces conversion of Tconvs into iTregs, FOXP3– Tconvs were 
sorted from FOXP3-red fluorescent protein reporter knockin 
mice (Foxp3-RFP mice) (Figure 3A), stained with CFSE, and trans-
ferred into naive WT congenic animals that were then treated 
with control IgG or anti-CD45RB. Anti-CD45RB treatment 
had no effect on the frequency (Figure 3B) or on the number of 
cells newly expressing FOXP3+ (Figure 3C), indicating that anti- 
CD45RB does not induce conversion of Tconvs into iTregs. Of 
note, anti-CD45RB had no effect on the proliferation of Tconvs 
(data not shown and Figure 4, D and E).
To assess how anti-CD45RB affects nTregs, CFSE-stained, 
sort-purified FOXP3+ cells from Foxp3-RFP mice (Figure 3A) 
were transferred into naive WT congenic animals, using a pro-
cedure analogous to that described above. In steady state (IgG-
treated controls), 44% of Tregs underwent HP over 10 days 
(Figure 4A). Anti-CD45RB significantly enhanced HP of trans-
ferred nTregs, with 55% undergoing proliferation. Of note, anti- 
CD45RB preferentially enhanced the proliferation of the nTregs 
Figure 2. Anti-CD45RB Treg induction occurs independently of thymic output. (A) 
Number of FOXP3+CD4+ cells induced by anti-CD45RB (spleen, day 10) in euthymic or 
thymectomized animals relative to that of naive untreated mice (n = 5 mice per group in 
2 independent experiments). (B) Number of FOXP3–CD4+ or FOXP3+CD4+ cells recovered in 
spleens of congenic recipients 10 days after adoptive transfer of CD4+ T cells into untreated 
and anti-CD45RB–treated mice (n = 10 mice per group from 4 independent experiments).
Figure 3. Anti-CD45RB does not induce iTregs in adoptively transferred Tconvs. (A) Representative flow cytometry plots showing sort gates used to 
isolate FOXP3+ or FOXP3– CD4+ cells from Foxp3-RFP congenic (Thy1.1) mice (top row) and purity assessment after sort (bottom row). Numbers represent 
percentage of events in each gate. (B) Representative flow cytometry plots of live CD4+ cells recovered after adoptive transfer of highly purified  
FOXP3–CD4+Thy1.1+ cells (obtained as in A) into WT congenic mice that were then treated with control IgG or anti-CD45RB (examined in spleens on day 10). 
Numbers indicate average (± SD) percentage of transferred (Thy1.1+CD4+) cells recovered among total live CD4+B220– cells and FOXP3 expression within the 
Thy1.1+-transferred cell population. (C) Number of FOXP3–CD4+ and FOXP3+CD4+ cells from from right column in B after anti-CD45RB, relative to control IgG 
(n = 9 mice per group from 3 independent experiments).
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Treg proliferation through augmented IL-2R signaling. CD4 cells 
isolated from mice 10 days after treatment with either control IgG or 
anti-CD45RB were exposed to IL-2 ex vivo and stained for pSTAT-5 
(34). Reflecting low expression of the high-affinity IL-2R (CD25) in 
the steady state, a very small fraction (~2%) of Tconvs isolated from 
either IgG control- or anti-CD45RB–treated mice had detectable 
pSTAT-5 upon IL-2 exposure (Supplemental Figure 2). In contrast, 
approximately 80% of Tregs from IgG-treated mice rapidly phos-
phorylated STAT-5 in the presence of IL-2 (Supplemental Figure 
2). However, there was no difference in STAT-5 phosphorylation in 
response to IL-2 by Tregs isolated from anti-CD45RB–treated mice. 
This suggests that anti-CD45RB–induced Treg proliferation in vivo 
is not due to enhanced IL-2R signaling in Tregs.
CD45 ligation specifically enhances Treg proliferation in response 
to cognate antigen. The requirement for class II expression on DCs 
for Treg HP indicates that Treg HP is driven by endogenous anti-
gen (17). To determine whether the presence of cognate antigen 
is required for anti-CD45RB–mediated proliferation of Tregs, we 
used TCR transgenic CD4+ OT-II cells. CFSE-labeled OT-II CD4+ 
cells (~3% FOXP3+) were adoptively transferred into congenic WT 
recipients that were untreated, treated with anti-CD45RB, immu-
promote Treg survival in the periphery (30, 31), we determined 
whether this pathway was involved in the anti-CD45RB–medi-
ated increase in Tregs.
We generated mice in which TGFβRII could be conditionally 
deleted by crossing Tgbr2fl/fl mice (32) with Ubc-ERT2-Cre mice. 
Sort-purified CD25+CD4+ cells from Tgbr2fl/fl × Ubc-ERT2-Cre mice 
were adoptively transferred into replete congenic mice. Recipients 
were then treated with tamoxifen for 5 days to delete TGFβRII. 
Two days later, mice were treated with either control IgG or 
anti-CD45RB and assessed on day 10. In both anti-CD45RB and 
control IgG-treated mice, approximately 85% of the transferred 
CD4+ cells lost TGFβRII cell surface expression (data not shown). 
Transferred cells that remained TGFβRII+ served as an internal 
control. Compared with control IgG treatment, anti-CD45RB sig-
nificantly increased the number of Tregs recovered, regardless of 
whether they had lost or maintained TGFβRII expression (Supple-
mental Figure 1C). These data indicated that TGF-β signaling is 
not essential for anti-CD45RB–mediated increase in Tregs.
CD45 ligation does not promote IL-2R signaling in Tregs. Since 
Treg homeostasis relies on IL-2R signaling, and CD45 can act as a 
JAK PTPase (33), we asked whether anti-CD45RB was promoting 
Figure 4. Anti-CD45RB increases Tregs by augmenting HP of nTregs. (A) Flow cytometry plots of live CD4+ cells recovered after adoptive transfer of highly 
purified FOXP3+CD4+Thy1.1+ cells (obtained as in Figure 3A) into control IgG- or anti-CD45RB–treated WT congenic mice (examined in spleen on day 10).  
Numbers indicate average (± SD) percentage of transferred cells (Thy1.1+CD4+), FOXP3 expression within transferred cells, and CFSE dilution among  
FOXP3+-transferred cells (n = 8 mice per group, 4 independent experiments). *P < 0.05 vs. control IgG. (B) Number of recovered FOXP3+ cells from right 
column in A, relative to control IgG. (C) Distribution (CFSEbright vs. CFSElo) of increased FOXP3+ cells in response to anti-CD45RB treatment over control 
IgG from right column in A. Squares represent individual mice, and bars show averages. (D) Flow cytometry plot of CFSE dilution profiles of FOXP3–CD4+ 
and FOXP3+CD4+ cells recovered after transfer of total CD4+ T cells into congenic mice that were untreated or treated with anti-CD45RB (examined in 
spleens on day 10; n = 10 mice per group, 4 independent experiments). Numbers represent average (± SD) percentage of CFSElo. *P < 0.05 vs. untreated. (E) 
Number of CFSEbright and CFSElo cells from D, relative to control IgG. (F) Flow cytometry histograms and average (± SD) percentage of BrdU incorporation in 
endogenous FOXP3– and FOXP3+CD4+ cells from untreated and anti-CD45RB–treated mice (day 10). Mice were fed BrdU on days 7–10 (n = 4 mice per group, 
2 experiments; *P = 0.01 vs. untreated).
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cyte function antigen-1 (LFA-1) on T cells through “inside-out” sig-
naling (35–38). This led us to ask whether anti-CD45RB could affect 
Treg motility, promote Treg/DC interactions, and preferentially 
enhance Treg antigen responsiveness in vivo. First, we examined 
the effect of anti-CD45RB on surface expression of representative 
chemokine receptors and integrins. While anti-CD45RB had no 
effect on chemokine receptors CCR4, CCR5, or CCR6, it increased 
CCCR3 on both Tconvs and Tregs (Figure 6A). LFA-1 (CD11a) and 
integrin β1 (CD29) are well expressed on both Tregs and Tconvs, 
with a slightly higher level of expression observed on Tregs. Anti-
CD45B induced a marginal increase in the expression of both 
CD11a and CD29 on Tregs. However, increased surface expression 
does not necessarily correlate with the high-affinity conformation 
necessary for firm binding of integrins to their ligands. Therefore, 
we addressed this using in vitro motility assays described below.
nized with ovalbumin, or treated and immunized. Ovalbumin 
exposure induced a multifold increase in proliferating OT-II Tregs 
compared with that in unimmunized mice (day 7; Figure 5). The 
combination of anti-CD45RB with ovalbumin exposure resulted 
in a further 2-fold increase in the number of proliferating Tregs, 
compared with that after exposure to ovalbumin alone (Figure 5). 
While ovalbumin exposure markedly enhanced proliferation of 
Tconvs, anti-CD45RB had no further effect. In the absence of cog-
nate antigen, anti-CD45RB had no effect on either Tconv or Treg 
OT-II cells. Thus, anti-CD45RB specifically expands Tregs in an 
antigen-dependent and antigen-specific manner.
CD45 ligation preferentially reduces Treg motility, leading to 
increased Treg contact time with DCs. TCR signaling requires inter-
action with MHC II antigen complexes, a process that depends on 
stable T cell/DC interactions resulting from activation of lympho-
Figure 5. Anti-CD45RB augments nTregs response to cognate antigen 
specifically. Number of FOXP3–CD4+ CFSElo and FOXP3+CD4+ CFSElo OT-II 
T cells recovered after adoptive transfer of OT-II CD4+ T cells into WT con-
genic mice that were untreated or treated with anti-CD45RB, ovalbumin 
(Ova), or ovalbumin and anti-CD45RB. Average ± SEM is shown (n = 3–7 
mice per group from 3 independent experiments).
Figure 6. Anti-CD45RB specifically inhibits integrin-dependent motility of Tregs. (A) Representative flow cytometry histograms of surface expression of 
indicated proteins on FOXP3– and FOXP3+CD4+ T cells from spleens of mice 10 days after control IgG or anti-CD45RB treatment. Gated on live CD4+B220–
CD8a– lymphocytes. n = 3 mice per group. (B) Representative cell-tracking diagrams of rested FOXP3– and FOXP3+CD4+ T cells on ICAM-1–coated plates with 
or without the addition of anti-CD45RB in graded concentrations. Axis numbers indicate cell position from origin (μm). (C) Mean velocity and displacement 
values of the tracks from B. Between 21 and 84 cells were tracked in each group (from 2 independent experiments). A third independent experiment gave 
similar results (data not shown). (D) Mean velocity and displacement values of rested FOXP3– and FOXP3+CD4+ T cells on fibronectin-coated plates with 
the addition of control IgG or anti-CD45RB (1 μg/ml). Between 246 and 1,091 cells were tracked in each group (from 2 independent experiments). Horizontal 
bars indicate median values. *P < 0.05 vs. untreated or control IgG, **P < 0.05 vs. FOXP3–CD4+ for each condition.
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To examine the effect of anti-CD45RB on LFA-1 adhesion, we 
assessed the motility of CD4+ cells from Foxp3-GFP (GFP reporter) 
mice on plates coated with ICAM-1, as we previously reported (39, 
40). LFA-1 has a predominant effect on T/DC interactions com-
pared with β1 integrins (41). Tregs and Tconvs bound equally to 
the plates (i.e., >90% of cells), while cellular adhesion was almost 
completely absent in the presence of anti–ICAM-1 or on uncoated 
plates (data not shown).
We found that CD45 ligation preferentially affected motility 
of Tregs (Figure 6, B and C). While the addition of anti-CD45RB 
at 1 to 10 μg/ml slowed Tconvs, only 0.1 μg/ml anti-CD45RB was 
necessary to reduce the motility of Tregs, as seen by the restricted 
migration pattern (Figure 6B). This difference was underscored 
by measurement of mean velocity and displacement in which a 
concentration of 10 μg/ml was needed to slow Tconvs to the same 
degree as that seen for 0.1 μg/ml with Tregs (i.e., 100-fold dif-
ference in sensitivity; Figure 6C). Even at the highest dose tested 
(10 μg/ml), anti-CD45RB had a significantly greater effect on 
motility of Tregs than on that of Tconvs. Anti-CD45RB also 
exerted a selective slowing of Tregs on fibronectin-coated plates, 
albeit smaller in magnitude than with LFA-1 (comparing Figure 6C 
and Figure 6D). This shows that anti-CD45RB also increased 
adhesion of β1 integrins (primarily VLA-4 and VLA-5). We there-
fore found that anti-CD45RB preferentially slows integrin-medi-
ated motility of Tregs, and further, this can occur in the absence 
of concurrent TCR signaling.
Next, we tested the effect of anti-CD45RB on Treg and Tconv 
motility in vivo using 2-photon intravital microscopy (2PIM). 
The spleen red pulp was examined because it is both accessible 
by 2PIM and has an extensive network of DCs, which facilitates 
the intravital imaging of DC/T cell interactions in the steady state 
(42). FOXP3+ Tregs from control IgG or anti-CD45RB–treated 
Foxp3-RFP mice were sorted on day 4, labeled with distinct fluor-
escent dyes, and cotransferred into naive syngeneic recipients 
expressing yellow fluorescent protein (YFP) under the CD11c pro-
moter. Using the same approach, additional sets of mice received 
cotransfer of FOXP3– Tconvs from control IgG- and from anti- 
CD45RB–treated Foxp3-RFP mice. Twenty-four hours later, the 
motility of control IgG- and anti-CD45RB–treated Tregs and 
Tconvs was compared in the spleen using 2PIM over 30-minute-
Figure 7. CD45 ligation enhances Treg/DC contacts in vivo. Naive Cd11c-YFP mice received cotransfer of either FOXP3–CD4+ cells isolated on day 4 from 
mice treated with IgG or anti-CD45RB or FOXP3+CD4+ cells isolated on day 4 from mice treated with IgG or anti-CD45RB. (A) Representative cell tracks 
from 30-minute time-lapse images acquired by 2PIM of splenic red pulp 1 day after cotransfer of control IgG- or anti-CD45RB–exposed FOXP3–CD4+ or 
FOXP3+CD4+ cells. Images correspond to Supplemental Video 1. Bottom row shows cell tracks only (scale bar: 50 μm). (B–D) Quantification of motility and T 
cell/DC interactions from images in A. (B) T cell/DC contact duration time (numbers indicate fold increase vs. control IgG), (C) number of T cell/DC contacts 
per T cell track, (D) total traveled distance per track. Bars represent mean. (E and F) Cell tracks from images in A were analyzed (E) for arrest coefficient 
(fraction of time a T cell has an instantaneous velocity ≤2 μm/min over the entire tracking time) and (F) for mean velocity, and plotted as frequency distri-
bution. Vertical dashed lines show mean, and numbers represent percentages of tracks with a value of ≥0.6 (E) and a value of ≤3 μm/min (F) within each 
group. P values compare fractions of control vs. anti-CD45RB–treated CD4 tracks within cutoffs defined above. n = 4 mice per group from 4 independent 
experiments. 213 control IgG FOXP3–, 199 anti-CD45RB FOXP3–, 72 control IgG FOXP3+, and 103 anti-CD45RB FOXP3+ tracks were analyzed from 11 time-
lapse images per group.
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long time-lapse images. Of note, this approach examines the 
behavior of Tregs and Tconvs expressing polyclonal TCRs in 
absence of exogenous antigen. In steady state (comparing cells 
from control IgG-treated mice), Tregs traveled faster and spent 
less time arrested compared with Tconvs, making short (aver-
aging 2.8 minutes for Tregs and 8.4 minutes 
for Tconvs) and more frequent contacts with 
DCs (Figure 7 and Supplemental Video 1). In 
comparison to control Tregs, those treated 
with anti-CD45RB exhibited a 60% increase 
in contact duration, with fewer DC partners 
(number of contacts) and a reduced travel dis-
tance (Figure 7, A–D, and Supplemental Video 
1). Consequently, anti-CD45RB–treated Tregs 
exhibited a 2-fold increase in the proportion of 
cells with an arrest coefficient ≥0.6 or a mean 
velocity of ≤3 μm/min when compared with 
control IgG-treated Tregs (Figure 7, E and F). 
In contrast, Tconv behaviors remained mostly 
unaffected by anti-CD45RB (Figure 7 and Sup-
plemental Video 1). Although an augmenta-
tion in the contact duration was detected, the 
average increase induced by anti-CD45RB 
was only 20% for Tconvs, compared with 60% 
for Tregs (Figure 7B), and there was no change 
in any other motility parameters. Overall, 
these data show that CD45 ligation preferen-
tially slowed the motility of Tregs while con-
currently increasing Treg/DC contact times.
CD45 ligation increases NFAT activation in 
Tregs. The increase in contact times would be 
expected to generate an increase in signaling 
that leads to the observed expansion of Tregs. 
To assess this, the effect of anti-CD45RB on 
NFAT translocation into the nucleus was 
examined (Figure 8). NFATc1 expression and 
localization were evaluated in Tconvs and 
Tregs from untreated and anti-CD45RB–
treated mice using confocal microscopy and 
flow cytometry. In Tconvs, anti-CD45RB had 
no effect on either total (flow cytometry; Fig-
ure 8A) or nuclear (confocal imaging; Figure 
8, B and C) NFATc1 expression as compared 
with that in untreated mice. In contrast, 
anti-CD45RB significantly increased both 
total and nuclear NFATc1 expression in Tregs 
(Figure 8). Consistent with increased Treg/
DC dwell times, this observation suggests 
that anti-CD45RB augments Treg prolifera-
tion by enhancing TCR-driven NFAT nuclear 
translocation. As a functional correlate, the 
calcineurin inhibitor cyclosporin A (CsA) sig-
nificantly reduced both the absolute number 
and HP of transferred FOXP3+ Tregs com-
pared with that in untreated animals, and 
these were not restored to baseline by the 
addition of anti-CD45RB (Figure 9). This 
effect could be attributable to CsA-mediated inhibition of IL-2 
secretion by Tconv, which is essential for Treg homeostasis (14, 
21). To address this, mice treated with CsA and anti-CD45RB 
also received daily recombinant IL-2 (rIL-2) at a dose that aug-
ments Treg number and HP in the absence of CsA (data not 
Figure 8. Increased NFAT activation in Tregs after CD45 ligation. (A) Representative NFATc1 
immunofluorescence histograms (by flow cytometry) in FOXP3–CD4+ and FOXP3+CD4+ cells 
from spleens of untreated or anti-CD45RB–treated B6 WT mice (day 7). (B) Representative 
confocal microscopy images of sorted FOXP3– or FOXP3+CD4+ cells from spleens of untreated or 
anti-CD45RB–treated B6 WT mice on day 7. DAPI was used to stain DNA (scale bar: 2 μm). (C) 
Box-and-whiskers plot of mean absolute nucleic NFATc1 fluorescence intensity staining from con-
focal images described in B. Between 47 and 280 individual cells (compiled from 5 to 6 mice in 2 
independent experiments) were analyzed in each group. Boxes delineate quartiles, whiskers show 
5–95 percentile, and values beyond that range are shown as dots. A third independent experiment 
gave similar results (data not shown).
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gen. In agreement, transplant studies suggest that anti-CD45RB 
promotes antigen-specific Tregs (25, 29, 54). For example, anti- 
CD45RB generates donor-specific tolerance that is abrogated with 
depletion of Tregs by anti-CD25. Moreover, CsA prevents Treg 
expansion by anti-CD45RB (Figure 9) and blocks anti-CD45RB–
mediated tolerance (28).
As we showed previously (16), a fraction of Tregs undergoes 
multiple rounds of division, while almost half do not divide during 
the observation period (Figure 4, A and D). nTregs express a largely 
distinct TCR repertoire with increased self-reactivity compared 
with that of Tconvs (55). Presumably, Tregs undergoing more 
rapid HP exhibit TCRs with higher affinity to endogenous antigens 
or antigens from gut flora. Our findings suggest that CD45 ligation 
preferentially increases proliferation of Tregs already responding 
to antigen since the nonproliferating pool is largely unchanged 
(Figure 4, A and D). This could occur by increasing the efficiency 
of antigen presentation and may promote outgrowth of Tregs with 
the highest affinity for foreign antigens and self-antigens. Since 
thymic-derived nTregs represent the majority (>96%) of FOXP3+ 
Tregs present in the periphery, anti-CD45RB is most likely target-
ing these cells. However, anti-CD45RB may also affect the 4% of 
the Treg population induced in the periphery.
Upon initial TCR ligation, LFA-1 undergoes conformational 
change, resulting in increased affinity for its ICAM-1 ligand (35–
38). This reduces T cell motility and promotes stable conjugates 
with APCs. Longer contact times increase the efficiency of T cell 
activation by providing time for recruitment of additional MHC-
peptide complexes into the contact region (56). In this regard, 
FOXP3 was shown to induce expression of the adhesion mole-
cule, Neuropilin-1, which augments Treg contact time with DCs 
and promotes their activation compared with Tconvs (56). We 
now show that anti-CD45RB preferentially reduces the motil-
ity of Tregs, leading to a 2-fold increase in the number of Tregs 
that arrested their movement, resulting in more prolonged inter-
actions with fewer DCs (Figure 7, B and C). This, in turn, was 
correlated with increased downstream signaling, as evidenced 
by enhanced nuclear translocation of NFAT in Tregs. For exam-
shown). While rIL-2 restored Treg number and HP to baseline 
levels observed in untreated mice, they remained below that 
observed in mice treated with anti-CD45RB alone (Figure 9). 
This suggests that NFAT activation plays an essential role in 
anti-CD45RB–mediated Treg expansion. Concordantly, CsA has 
also been shown to interfere with tolerance induction by anti- 
CD45RB (28). Taken together, our data indicate that CD45 ligation 
enhances Treg conjugate formation with DCs, promotes TCR sig-
naling, and enhances antigen-driven expansion of Tregs in vivo.
Discussion
Despite their key role in establishing and maintaining tolerance 
to self-antigens and foreign antigens, the best approach toward 
expanding Tregs for clinical application remains uncertain. The 
transfer of ex vivo–expanded Tregs in solid organ transplantation 
and autoimmunity faces practical limitations, including a require-
ment for large numbers of cells, possibly infused repeatedly, to try 
to effect a significant increase in Tregs (6, 43–46). In comparison, 
a reagent-based therapeutic approach for in vivo expansion of 
Tregs would be more practical. Although targeting Treg expansion 
in vivo has been described previously, these approaches appear 
nonspecific in the face of an ongoing immune response (22–24) 
or expanding CD25lo Tregs in a non-antigen–specific manner by 
enhancing their IL-2 sensitivity with anti-TNFRSF25 (47). We now 
show that anti-CD45RB expands Tregs in a novel manner by pro-
moting Treg/DC interactions and augmenting antigen-mediated 
expansion of nTregs in vivo.
In the steady state, nTregs undergo a high rate of turnover, 
making them particularly sensitive to factors that affect their pro-
liferation or survival (16, 48). In this regard, anti-CD45RB alters 
normal homeostatic constraints, resulting in a significant increase 
in Treg proliferation. The preferential expansion of nTregs may 
provide an advantage compared with iTregs, based on their more 
stable FOXP3 expression and suppressive phenotype, coupled 
with differences in gene expression and a higher affinity TCR 
repertoire (2, 49–53). Importantly, anti-CD45RB specifically 
enhances the response of Tregs, but not of Tconvs, to cognate anti-
Figure 9. Increased Treg HP by anti-CD45RB 
depends on intact calcineurin activity. (A) 
Representative flow cytometry CFSE dilution 
profiles of FOXP3+CD4+ cells 10 days after adop-
tive transfer of congenic CFSE-stained CD4+ T 
cells in spleens of mice that were untreated or 
treated with CsA, anti-CD45RB, anti-CD45RB 
and CsA, or anti-CD45RB, CsA, and rIL-2. 
Numbers show representative percentage of 
events in each gate. (B) Number of transferred 
FOXP3+CD4+ cells (relative to untreated mice) in 
spleens 10 days after treatment as in A  
(n = 5–8 mice per group). (C) Number of trans-
ferred FOXP3+CD4+ cells that have proliferated 
(CFSElo) or have not proliferated (CFSEbright) in 
spleens 10 days after treatment as in A (relative 
to untreated mice). *P < 0.05 vs. untreated,  
**P < 0.05 vs. anti-CD45RB.
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(64). Tgbr2fl/fl mice were generated as described previously (30, 32) 
and were crossed with Ubc-ERT2-Cre mice in our facility.
Antibodies and immunofluorescence. Purified anti-CD45RB mAb 
(MB23G2) and control rat IgG2a were from BioXCell. Biotin or fluoro-
chrome-conjugated mAbs against CD4, CD25, CD19, CD45RB, 
CTLA-4, FOXP3, CD44, CD45.1, CD62L, CD69, CD90.1, CD90.2, 
B220, CD11b, CD16/32, CD8, CD11a, CD29, CCCR3, CCR4, CCR5, 
CCR6, mouse IgG, BrdU, pSTAT-5, annexin V, and Ig control anti-
bodies were from BD Biosciences and eBioscience; anti-NFATc1 mAb 
(7A6) was from Santa Cruz Biotechnology and Biolegend, and anti- 
TGFβRII was from R&D Systems. Dead cells were labeled using Fix-
able Dead Cell Stain (Invitrogen). CD45RB expression was analyzed 
by staining with directly conjugated anti-CD45RB (clone 16A), which 
does not cross-react with the epitope bound by MB23G2 (25, 28). 
Negative controls used appropriate Ig fluorochrome conjugates. Flow 
acquisition was performed on LSRII Fortessa, LSRII, or FACSCalibur 
analyzers (BD Biosciences), and data were analyzed using Flowjo soft-
ware (Tree Star). 1 × 106 to 10 × 106 events were acquired per sample. 
Quantitative cell numbers were calculated according to total live cell 
counts recovered from individual lymphoid compartments.
In vitro suppression assays. 10 days after initial treatment, CD25+CD4+ 
cells were isolated from spleens and lymph nodes of B6 recipients by 
cell sorting (FACSAria, BD Biosciences). These CD4+CD25+ cells were 
examined for their ability to inhibit 105 fresh CD4+CD25– B6 responders 
stimulated with 2 × 105 irradiated BALB/c splenocytes. Proliferation was 
assessed on day 5 by H3-thymidine uptake.
Thymectomy. As indicated, mice underwent thymectomy as 
described previously (29). Briefly, a plastic tip was introduced into the 
mediastinum through a sternotomy, and the thymus was removed by 
suction. Successful thymectomy was reassessed at the time of sacrifice.
Treatment protocols. Mice received 3 doses of anti-CD45RB 
(MB23G2; 100 μg; i.v.) on days 0, 1, and 5 (25, 28). Control recipi-
ents were untreated or treated with control IgG using the same dos-
age. Some recipients were exposed to alloantigen by i.p. injections 
of 25 × 106 splenocytes from BALB/c mice or by transplanting 200 
BALB/c islets under the left kidney capsule on day 0, as we previously 
described (65). Thymectomy was performed on day –7. CsA was given 
i.p. daily from day 0 at 40 mg/kg/d. Recombinant mouse IL-2 (eBio-
science) was injected i.p. daily at 1.5 μg. Tamoxifen in corn oil (Sigma- 
Aldrich) was given at 50 mg/d i.p.
Adoptive cell transfer. CD4+ cells from spleens and lymph nodes of 
B6 Thy1.1 mice were enriched by negative selection using BioMag beads 
(Qiagen) or EasySep (Stem Cell Technologies), stained with CFSE (2.0–
2.5 μM 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester; 
Invitrogen) as indicated, and transferred into sex-matched B6 (Thy1.2) 
mice on day –1 (10 × 106 to 30 × 106 cells per recipient). CD4+RFP– or 
CD4+RFP+ cells from spleens and lymph nodes of Foxp3-RFP mice (B6; 
Thy1.1) were sorted using a FACSAria cell sorter (BD Biosciences). In a 
given experiment, equal numbers of RFP– cells (range 9 × 106 to 10 × 106; 
99.9% pure) or equal numbers of RFP+ cells (range 2 × 106 to 3 × 106; 
99.2% pure) were injected i.v. into sex-matched B6 Thy1.2 mice on day –1 
and left untreated or treated with control IgG or anti-CD45RB. In sepa-
rate experiments, highly pure CD4+CD25+ cells from spleens and lymph 
nodes of Tgbr2fl/fl × Ubc-ERT2-Cre mice (B6; Thy1.2) were sorted using a 
FACSAria cell sorter (BD Biosciences) and transferred into sex-matched 
B6 CD45.1 mice on day –6 and treated with tamoxifen (on days –6 to 
–2) and anti-CD45RB (days 0, 1, and 5) or treated with tamoxifen and 
ple, 32% of Tregs from anti-CD45RB–treated animals expressed 
nuclear NFAT equal or above that of the top 5% of Tregs from 
untreated mice (Figure 8C). NFAT can promote transcription of 
genes directly involved in proliferation and transcriptional activity 
of FOXP3, which may itself be involved in Treg homeostasis and 
enhanced survival (57). In support, we show that NFAT signaling 
plays a role in anti-CD45RB–mediated Treg proliferation (Figure 
9). These anti-CD45RB–mediated changes act predominantly 
through an LFA-1–dependent pathway, and this occurred in the 
absence of concurrent TCR engagement (Figure 6). In this regard, 
previous work by Sakaguchi and colleagues showed a reduction 
of in vitro aggregation of Tregs on DCs in absence of LFA-1 bind-
ing (58). Together, our data indicate that differential regulation of 
LFA-1 adhesion, as well as β1 integrins, by Tregs and Tconvs is sub-
ject to therapeutic manipulation.
CD45 plays a critical role in TCR signaling by regulating the 
phosphorylation of LCK and FYN protein tyrosine kinases (PTKs). 
Depending on the tyrosine residue dephosphorylated, CD45 can 
either increase or decrease PTK activity, and this may depend 
on timing and colocalization with different pools of substrate 
(59–62). As a further complexity, the role of the different CD45 
isoforms remains enigmatic. Further study will be required to 
determine how ligation of CD45RB specifically affects signaling 
leading to increased LFA-1 adhesion, resulting in altered effec-
tive Treg/DCs interactions and enhanced expansion. While this 
could relate to differences in CD45RB expression between Tregs 
(CD45RBlo) and naive Tconvs (CD45RBhi), this would not explain 
why anti-CD45RB did not enhance proliferation of activated 
Tconvs (CD45RBlo) (63). In this regard, Tregs and Tconvs exhibit 
differences in the regulation of their interactions with APCs. For 
example, we showed recently that, in contrast to Tconv/APC con-
jugation, Treg/APC conjugation is not inhibited by CTLA-4 sig-
naling (39, 40). Our current data are the first to demonstrate that 
such differences in regulation of APC conjugation between Tregs 
and Tconvs can be targeted for therapeutic purposes.
Despite intense focus on Treg biology, studies assessing how 
these cells can be specifically induced through intrinsic biological 
processes to promote tolerance are limited. Our study unexpect-
edly uncovered that CD45 ligation can rapidly increase Tregs in 
vivo by promoting antigen-mediated expansion of nTregs. It is 
now clear that Treg/APC interactions are differentially regulated 
from Tconv/APC interactions and may be specifically targeted to 
expand Treg numbers. Further dissection of the signals linking 
CD45 to Treg HP, “inside-out” signals, and survival will provide 
new insight and allow identification of additional therapeutic tar-
gets. However, this discovery may allow direct therapeutic expan-
sion of Tregs in vivo and may be useful to augment the relative 
expansion of cultured Tregs after transfer.
Methods
Animals. Sex-matched 6- to 10-week-old BALB/c (H-2d), C57BL/6 
(B6; H-2b), B6.PL-Thy1a/Cy (Thy1.1), B6.SJL-Ptprca Pepcb/BoyJ 
(CD45.1), B6.Cg-Tg(Itgax-Venus)1Mnz/J (Cd11c-YFP), B6.Cg-Tg(Ubc- 
ERT2-Cre)1Ejb/J (Ubc-ERT2-Cre), B6.Cg-FOXP3tm2Tch/J (Foxp3- 
GFP), and B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II) mice from the 
National Cancer Institute or The Jackson Laboratory were used. Foxp3- 
RFP knockin mice (B6, H-2b) were generated as described previously 
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
4 6 1 2 jci.org   Volume 124   Number 10   October 2014
sion ×25 objective (NA = 1.05; Olympus). Image rendering, tracking 
of adoptively transferred cells from time sequence of image stacks, 
motion artifact correction, and masking were performed using Imaris 
software. Tracks < 2 minutes were excluded. Each track was inspected 
manually to ensure accuracy. Motility parameters were generated 
using Imaris (Bitplane), while contact parameters were measured and 
compiled manually. Videos were edited using Photoshop CS6 (Adobe).
Nuclear NFATc1 assessment. CD4+ T cells from spleens of B6 mice 
that were left untreated or received anti-CD45RB were enriched 
and stained for FOXP3 and NFATc1 expression. The DNA of sorted 
FOXP3– and FOXP3+ cells was stained with DAPI (Sigma-Aldrich), and 
images were acquired by confocal microscopy (Olympus). The nuclei 
of individual cells were delineated, and the mean fluorescence inten-
sity was measured using ImageJ software (NIH). Mean background 
fluorescence intensity and mean isotype fluorescence intensity were 
subtracted from individual values.
Statistics. Nonparametric Mann-Whitney test was used for 
statistical analyses, except as noted below. The binomial test of 
proportions was used to address impact of treatment on the frac-
tion of cells with arrest coefficient ≥0.6 (Figure 7E) or with mean 
velocity ≤3 μm/min (Figure 7F). Differences were considered to be 
significant at P < 0.05. Bar graphs show mean ± SD, unless otherwise 
stated in the figure legend.
Study approval. Mice were housed with food and water ad libi-
tum. Studies were performed in compliance with NIH guidelines and 
approved by the Institutional Animal Care and Use Committee at the 
University of Pittsburgh.
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control IgG. For 2-photon intravital imaging of spleens, CD4+RFP– or 
CD4+RFP+ cells from spleens and lymph nodes of Foxp3-RFP mice that 
received anti-CD45RB or control IgG were sorted on day 4, stained with 
CellTracker Violet (CTV) or CellTracker Orange (CTO; 2.0 μM; Invit-
rogen), and transferred into naive sex-matched Cd11c-YFP mice. Dyes 
were alternated between experiments.
Ex vivo IL-2R signaling assessment. Splenocytes from B6 mice that 
received control Ig or anti-CD45RB were exposed to 50 U/ml rmIL-2 
(eBioscience) for 15 minutes prior to fixation/permeabilization and 
pSTAT-5 staining.
In vitro live cell imaging for motility assays. Bead-enriched (Dynal) 
CD4+ T cells from Foxp3-GFP mice (used on ICAM-1-Fc–coated 
plates), or sorted CD4+FOXP3– and CD4+FOXP3+ T cells from Foxp3- 
RFP mice (used on fibronectin-coated plates), were activated with 
plate-bound anti-CD3 and anti-CD28 mAbs for 2 days. Cells were 
rested overnight before being added to 4 μg/ml ICAM-1-Fc– (R&D 
Systems) or fibronectin-coated (20 μg/ml) plates and incubated at 
37°C. Cell movement was recorded every 10 seconds for 20 minutes 
(for ICAM-1-Fc–coated plates) or every 5 seconds for 5 minutes (for 
fibronectin-coated plates) using Zeiss LSM710 or Nikon Eclipse Ti 
live cell imaging confocal microscopes, 488 nm laser excitation, and 
transmitted light. Data were analyzed using Velocity (Perkin Elmer) 
or Imaris (Bitplane) softwares. Measurements were performed on 
adhered cells only, distinguished from nonadhered cells by shape, 
including cell protrusions.
2PIM. Mice were anesthetized using isoflurane. Spleens of 
Cd11c-YFP mice were surgically exposed and supported using a cus-
tom-made device 1 day after cotransfer of CTO- or CTV-stained CD4+ 
RFP– (or CD4+ RFP+ in separate experiments) T cells from control IgG- 
or anti-CD45RB–treated Foxp3-RFP mice (4 days prior to cell sorting). 
Splenic blood perfusion, mouse rehydration, and physiological tem-
perature of 37°C were preserved and maintained throughout imaging. 
Two-photon laser scanning imaging was performed using an upright 
Olympus FV1000 MPE microscope (Olympus) and a Mai Tai Deep-
See femtosecond-pulsed Ti:sapphire laser (Spectra-Physics) tuned at 
860 nm. The tissue was line scanned, and fluorescence emission was 
captured by 3 nondescanned external photomultiplier tube detectors 
coupled to the following band-pass emission filters: 460–500 nm, 
520–560 nm, and 570–650 nm. Time-lapse images were acquired 
using Fluoview software (Olympus). Stacks of 12 optical sections were 
acquired every 30 seconds for 30 minutes to provide image volumes 
of 30 μm (25- to 55-μm deep) in depth and around 450 μm in width 
and height at a resolution of 0.994 μm per pixel using a water immer-
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